When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Intuitive Surgical, Inc. (ISRG) .Intuitive Surgical currently has an average brokerage recommen ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Axon Enterprise (AXON) .Axon currently has an average brokerage recommenda ...

Core Viewpoint - DLocal (DLO) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive earnings outlook that may lead to increased stock price [1][3]. Earnings Estimates and Revisions - The Zacks Consensus Estimate for DLocal's earnings per share (EPS) for the fiscal year ending December 2025 is projected at $0.62, reflecting a 21.6% increase from the previous year [8]. - Over the past three months, the consensus estimate for DLocal has risen by 9.9%, indicating a trend of increasing earnings estimates [8]. Zacks Rating System - The Zacks rating system classifies stocks based on earnings estimate revisions, with DLocal's upgrade positioning it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns [10]. - The Zacks Rank system has a strong historical performance, with Zacks Rank 1 stocks averaging an annual return of +25% since 1988 [7]. Impact of Institutional Investors - Changes in earnings estimates significantly influence institutional investors' valuation models, leading to buying or selling actions that affect stock prices [4]. - The correlation between earnings estimate revisions and stock price movements underscores the importance of tracking these revisions for investment decisions [6].

Core Viewpoint - Apogee Therapeutics Inc. (APGE) has seen a 9.9% increase in share price over the past four weeks, closing at $40.98, with analysts projecting a potential upside of 129.1% based on a mean price target of $93.88 [1][12]. Price Targets - The average price target consists of eight estimates ranging from a low of $78 to a high of $116, with a standard deviation of $11.05, indicating a potential increase of 90.3% to 183.1% from the current price [2][9]. - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement direction [9]. Earnings Estimates - Analysts are optimistic about APGE's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [11][12]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 9.2%, with three estimates moving higher and no negative revisions [12]. Analyst Consensus - APGE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential upside in the near term [13].

Core Viewpoint - Concentra Group (CON) has seen a 2.9% increase in share price over the past four weeks, closing at $22.03, with a mean price target of $28 indicating a potential upside of 27.1% [1] Price Targets and Analyst Consensus - The average price target consists of eight estimates ranging from a low of $25 to a high of $30, with a standard deviation of $1.85, suggesting a potential increase of 13.5% to 36.2% from the current price [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Market Sentiment - Analysts are optimistic about CON's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 1.5%, with three estimates moving higher and no negative revisions [12] Zacks Rank and Investment Potential - CON holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential for upside in the near term [13]

Group 1 - Birkenstock (BIRK) shares have increased by 4.1% over the past four weeks, closing at $54.76, with a mean price target of $68.88 indicating a potential upside of 25.8% [1] - The average of 17 short-term price targets ranges from a low of $57 to a high of $81, with a standard deviation of $7.34, suggesting a relatively high agreement among analysts [2] - Analysts are optimistic about BIRK's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] Group 2 - Over the last 30 days, the Zacks Consensus Estimate for BIRK's current year earnings has increased by 4%, with eight estimates moving higher and one lower [12] - BIRK holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]

Core Viewpoint - Monte Rosa Therapeutics (GLUE) has seen a 22.5% increase in share price over the past four weeks, closing at $5.01, with a potential upside indicated by Wall Street analysts' mean price target of $16.14, suggesting a 222.2% increase from the current price [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $3.98, where the lowest estimate of $10 indicates a 99.6% increase, and the highest estimate suggests a 299.2% surge to $20 [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts are optimistic about GLUE's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [11] - Over the last 30 days, three earnings estimates for the current year have been revised higher, leading to a 56.6% increase in the Zacks Consensus Estimate [12] Zacks Rank and Investment Potential - GLUE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside in the near term [13]

Group 1 - Phathom Pharmaceuticals, Inc. (PHAT) shares have increased by 184.1% in the past four weeks, closing at $8.92, with a mean price target of $18.50 indicating a potential upside of 107.4% [1] - The mean estimate consists of eight short-term price targets with a standard deviation of $8.09, where the lowest estimate is $5 (44% decline) and the highest is $28 (213.9% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11][12] Group 2 - The Zacks Consensus Estimate for the current year has risen by 16% over the last 30 days, with one estimate increasing and no negative revisions [12] - PHAT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, it suggests a positive direction for price movement [13]

Group 1 - The RealReal (REAL) stock closed at $5.71, showing a 13.1% gain over the past four weeks, with a mean price target of $10.10 indicating a potential upside of 76.9% [1] - The mean estimate consists of five short-term price targets with a standard deviation of $3.09, where the lowest estimate is $7 (22.6% increase) and the highest is $15 (162.7% increase) [2] - Analysts show strong agreement on the company's ability to report better earnings, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 64.3% over the past month, with no negative revisions [12] - REAL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting stock gains, they can indicate the direction of price movement [13]

Group 1 - ZipRecruiter, Inc. (ZIP) shares have increased by 43.4% over the past four weeks, closing at $6.25, with a mean price target of $8 indicating a potential upside of 28% [1] - The mean estimate consists of five short-term price targets with a standard deviation of $1.87, where the lowest estimate is $6 (4% decline) and the highest is $10 (60% increase) [2] - Analysts show a strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11] Group 2 - The Zacks Consensus Estimate for the current year has risen by 1.1% over the past month, with two estimates increasing and one decreasing [12] - ZIP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, it suggests a positive direction for price movement [13]